TamHao B. Nguyen has resigned from her position as Senior Vice President, Chief Financial Officer and Corporate Secretary of the Corporation and the Bank, effective February 21, 2025
Effective as of the Vignola Separation Date, Amy Burroughs, the Company’s Chief Executive Officer, has assumed the role of principal financial officer and David Strauss, the Company’s Vice President of Finance and Controller, has assumed the role of principal accounting officer of the Company, in each case on an interim basis.
On February 1, 2025, pursuant to, and subject to the terms of, the Vignola Transition Agreement, Mr. Vignola confirmed that his separation from employment was effective as of February 1, 2025 (the “Vignola Separation Date”) and resigned as of the Vignola Separation Date from all officer and director positions at the Company, the Subsidiary and any other subsidiary or affiliate.
Effective June 10, 2025, Mr. Malone shall be employed as the Company’s President and Chief Executive Officer (the “CEO Period”).
Appointed
Nadeem Moiz
President, Chief Financial Officer and Chief Operating Officer
Revance Therapeutics, Inc.
Effective
2025-02-06
Filed
February 6, 2025, 6:59 PM ET
the officers of Merger Sub immediately prior to the Effective Time became the officers of the surviving corporation, effective as of the Effective Time. The officers of Merger Sub immediately prior to the Effective Time were Jeffery A Bedard as Chief Executive Officer, Nadeem Moiz as President, Chief Financial Officer and Chief Operating Officer, and Shellie L. Hammock as Executive Vice President, General Counsel and Secretary.
Appointed
Jeffery A Bedard
Chief Executive Officer
Revance Therapeutics, Inc.
Effective
2025-02-06
Filed
February 6, 2025, 6:59 PM ET
the officers of Merger Sub immediately prior to the Effective Time became the officers of the surviving corporation, effective as of the Effective Time. The officers of Merger Sub immediately prior to the Effective Time were Jeffery A Bedard as Chief Executive Officer, Nadeem Moiz as President, Chief Financial Officer and Chief Operating Officer, and Shellie L. Hammock as Executive Vice President, General Counsel and Secretary.
Effective as of and contingent upon the Retirement, the Company intends to appoint Christiane Ohlgart, age 57, to serve as Chief Financial Officer of the Company (including as its Principal Financial Officer).
On February 6, 2025, the Board of Directors (the “Board”) of Escalade, Incorporated (“Escalade” or the “Company”) announced that Armin Boehm has agreed to become the Company’s new Chief Executive Officer and President.
On February 1, 2025, the Company appointed Srdjan (“Serge”) Tanjga, who served as Senior Vice President, Finance at MongoDB, Inc. (the “Company”), as the Company’s Interim Chief Financial Officer, effective February 1, 2025.
Departed
Stephen D. Sheldon
Chief Financial Officer and Chief Operational Officer
PaxMedica, Inc.
Effective
2025-01-31
Filed
February 6, 2025, 6:59 PM ET
On January 31, 2025, Stephen D. Sheldon, chief financial officer and chief operational officer of PaxMedica, Inc., a Delaware corporation (the “Company”), provided notice of his resignation as an executive officer of the Company, effective immediately.
On February 3, 2025, the Board of Directors (the “Board”) of the Company appointed Chath Weerasinghe as the Company’s Chief Financial Officer and Chief Operating Officer, effective February 3, 2025.
Effective February 10, 2025, Douglas W. McCurdy, age 59, will assume the role of Chief Financial Officer.
Role change
Mark Lee
Chief Financial Officer
Forge Global Holdings, Inc.
Effective
2025-01-20
Filed
February 6, 2025, 6:59 PM ET
the Company and Mr. Lee mutually agreed on January 7, 2025 that Mr. Lee would transition from his role as the Company’s Chief Financial Officer, effective January 20, 2025
On January 31, 2025, Yvonne Li, the Consulting Agreement by and between Senti Biosciences, Inc. (the “Company”) and Yvonne Li, the Company’s Interim Chief Financial Officer, expired in accordance with its terms.
appointed David Lillis as Chief Executive Officer, Jeff Mayfield as Chief Financial Officer and Priyen Patel as Chief Strategy and Legal Officer (collectively, the “Appointed Officers”), effective on the Announcement Date.
appointed David Lillis as Chief Executive Officer, Jeff Mayfield as Chief Financial Officer and Priyen Patel as Chief Strategy and Legal Officer (collectively, the “Appointed Officers”), effective on the Announcement Date.
On February 4, 2025, Jason Keyes, Interim Chief Executive Officer, and Marc Landy, Interim Chief Financial Officer, provided notice of their resignations from their positions with the Company effective as of the Announcement Date.
On February 4, 2025, Jason Keyes, Interim Chief Executive Officer, and Marc Landy, Interim Chief Financial Officer, provided notice of their resignations from their positions with the Company effective as of the Announcement Date.
On February 4, 2025, the Board of Directors of Ford Motor Company (“Ford” or “Company”) approved the appointment of Sherry House as Chief Financial Officer of the Company, effective February 6, 2025.
The Board of Directors of Aware, Inc. (“Aware”) appointed Ajay Amlani to serve as Chief Executive Officer and President of Aware and as a Class III member of the Board of Directors of Aware, effective February 3, 2025.
David K. Traverse resigned his positions as Interim Chief Executive Officer and President of Aware, effective February 3, 2025. Mr. Traverse remains Aware’s Chief Financial Officer.
On February 3, 2025 (the “Effective Date”), the Board approved the appointment of Mr. Lim as the Company’s permanent Chief Financial Officer, effective as of the Effective Date.
Departed
Mark Rothera
President and Chief Executive Officer
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
Departed
Michael Faerm
Chief Financial Officer
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
the Board appointed Craig R. Jalbert, age 63, as the Company's Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary, and sole member of the Board.
On February 3, 2025, the Board of Directors of the Company (the "Board") approved the appointment of Mr. Hoffman to serve as the Chief Executive Officer of the Company, effective February 6, 2025.
David Stefko, who was appointed interim Chief Executive Officer of the Company on March 26, 2024, will resign from such position effective February 6, 2025, but remain with the Company for a transition period in a non-executive capacity and will continue to serve as a member of the Board.
announced that Joakim Weidemanis, 55, will join the Company and succeed George Oliver as the Company’s Chief Executive Officer and principal executive officer.
announced that Joakim Weidemanis, 55, will join the Company and succeed George Oliver as the Company’s Chief Executive Officer and principal executive officer.
the Company also announced the departure of David Wilkinson from his role as President and Chief Executive Officer of the Company, effective as of February 4, 2025.
The Board of Directors (the “Board”) of NCR Voyix Corporation (the “Company”) has appointed James G. Kelly, the existing Executive Chair of the Board, to succeed David Wilkinson as President and Chief Executive Officer of the Company, effective February 4, 2025.
On February 1, 2025, Mikayla Gilbert, 32, was promoted (replacing Edward Myers) to serve as Chief Financial Officer of the Company.
Appointed
Cory Rosenberg
Chief Executive Officer, President, Acting Chief Financial Officer and Secretary
Qrons Inc.
Effective
2025-01-31
Filed
February 5, 2025, 6:59 PM ET
Cory Rosenberg was appointed as the Company’s Chief Executive Officer, President, Acting Chief Financial Officer and Secretary
Departed
Christopher Davenport
Chief Executive Officer
Auto Parts 4Less Group, Inc.
Effective
2025-01-30
Filed
February 5, 2025, 6:59 PM ET
On January 30, 2025, Christopher Davenport resigned from the Board of Directors and as Chief Executive Officer of both Assignors effective contemporaneous with the execution of the Assignments and effectuation of the Assignments.
On February 1, 2025, Royalty Management Holding Corporation (or the “Company”) was informed by Kirk Taylor, the Company’s Chief Financial Officer, that he will resign from such position effective February 1, 2025.
Appointed
Amanda Kruse
Chief Financial Officer and Principal Accounting Officer
Concurrently, effective February 1, 2025 and in connection with Kirk Taylor’s resignation, the Board appointed Amanda Kruse as the Company’s Chief Financial Officer and Principal Accounting Officer.
Departed
Calum Hughes
Chief Executive Officer
Allied Corp.
Effective
2025-01-30
Filed
February 5, 2025, 6:59 PM ET
Calum Hughes resigned as Chief Executive Officer and a Director of the Company.
Departed
Jamie L. Prah
Executive Vice President and Chief Financial Officer
On February 4, 2025 , Jamie L. Prah voluntarily resigned as Executive Vice President and Chief Financial Officer of CB Financial Services, Inc. (the “Company”) and its subsidiary bank, Community Bank (the “Bank”).
Effective as of February 5, 2025, Stephen Lasher was appointed Chief Financial Officer of the Company.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.